Market research
EOLS Evolus Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 504M
- P/E ratio
- Not available
- Analyst target
- 15
- Dividend yield
- Not available
- Beta
- 1.34
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 504M
- P/E ratio
- Not available
- Analyst target
- 15
- Dividend yield
- Not available
- Beta
- 1.34
About
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Research context
Evolus Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EOLS discussion.
5 years, 6 months ago
Evolus, Inc is currently in a long term uptrend where the price is trading 51.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.8.
Evolus, Inc's total revenue rose by 5.8% to $21M since the same quarter in the previous year.
Its net income has dropped by 663.0% to $-111M since the same quarter in the previous year.
Finally, its free cash flow grew by 74.9% to $-4M since the same quarter in the previous year.
Based on the above factors, Evolus, Inc gets an overall score of 4/5.